RAC3 and lung adenocarcinoma: In summary, our findings from in vitro and in vivo studies support the hypothesis that PSD, when used in combination with paclitaxel, can effectively downregulate RAC3 expression and inhibit paclitaxel resistance in lung adenocarcinoma cells.